The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to see if it is safe and effective to give CI-1012 to HIV-infected patients who do not have any symptoms of the disease. This study also examines how the body handles CI-1012.
Condition or disease
Patients receive 2 weeks of oral CI-1012 therapy in this open-label study, with 8 patients entered at each dose level studied.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 60 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients must have:
Serologic evidence of infection with HIV-1.
CD4+ cell count >= 200 cells/mm3.
HIV-1 RNA >= 10,000 copies/ml.
Patients with the following conditions are excluded:
Viral, fungal, or bacterial infection requiring therapy other than topical medications.
Prophylactic systematic antibacterial, antifungal or antiviral agents.
Antiretroviral therapy. NOTE:
Patient must be willing to remain off antiretroviral therapy for 1 week after completing study medication.
Experimental therapy for >= 4 weeks prior to initiation of study medication.
Antiretroviral treatment for 3 weeks prior to initiation of study medication.
Systemic steroids or anticancer agents for 4 weeks prior to initiation of study medication.